Key Segmentation:
By Technology
-
Next-Generation Sequencing (NGS)
-
PCR-Based Assays
-
Digital PCR
-
Others
By Application
-
Cancer Screening & Early Detection
-
Therapy Selection / Companion Diagnostics
-
Molecular Residual Disease (MRD) Monitoring
-
Recurrence Monitoring
By Sample Type
-
Blood
-
Urine
-
Others
By End User
-
Hospitals & Diagnostic Centers
-
Clinical & Reference Laboratories
-
Academic & Research Institutes
-
Biopharmaceutical & Biotech Companies
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company's specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Technology X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Guardant Health Inc, Natera Inc., Illumina Inc., F. Hoffmann-La Roche Ltd. (Foundation Medicine), and Exact Sciences Corporation, among others.
Key opportunities include expanding liquid biopsy adoption, increasing early cancer detection, growing applications in treatment monitoring, rising demand for minimal residual disease testing, and advances in sequencing technologies.
The market is driven by rising global cancer prevalence, growing clinical adoption of liquid biopsy as a non-invasive alternative to tissue biopsy, and continued advancements in next-generation sequencing and digital PCR technologies.
The Cancer Screening & Early Detection segment dominated the Circulating Tumor DNA Testing Market in 2025, accounting for approximately 34.80% market share.
The North America region dominated the Circulating Tumor DNA Testing Market in 2025 with a 51.20% market share, driven by advanced precision oncology infrastructure and strong reimbursement support for liquid biopsy testing.
